Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538926 | 0.91 | CNR1 (0.40) | CNR1CNR2MEN1KMT2AMAOB | |
| SCHEMBL7539911 | 0.88 | ATM (0.40) | UTS2RCNR1ATMCNR2MEN1 | |
| SCHEMBL7542541 | 0.85 | PPARG (0.38) | UTS2RCNR1ATMMEN1KMT2A | |
| SCHEMBL7536086 | 0.83 | CNR1 (0.41) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL7542604 | 0.79 | PPARG (0.41) | UTS2RCNR1ATMCNR2MEN1 | |
| SCHEMBL7542553 | 0.79 | NR4A2 (0.43) | CNR1ATMCNR2MEN1KMT2A | |
| SCHEMBL7564669 | 0.78 | PPARG (0.45) | CNR1ATMMAOB | |
| SCHEMBL7539906 | 0.78 | MEN1 (0.46) | UTS2RCNR1ATMCNR2MEN1 | |
| SCHEMBL7535741 | 0.78 | PPARG (0.44) | CNR1ATMMEN1KMT2AMAOB | |
| SCHEMBL7536484 | 0.77 | NPC1 (0.40) | ATMMEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414179-B1 | USEFUL AGENTS IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA, ARTHRITIS, INFLAMMATORY BOWEL DISEASE AND NEURODEGENERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | PLA2G4B, PLA2G1B, PLA2R1 | UTS2R 1674/4885CNR1 323/4885ATM 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.